Brokers who understand life sciences risk can help clients protect intellectual property, manage clinical trial liability and strengthen cyber defences. Australia's life sciences sector spans biotechnology, medical devices, digital health platforms, clinical research and advanced therapeutics, and its risk profile is growing as fast as its innovation pipeline. Cybercrime costs are escalating sharply, clinical trial volumes have grown significantly over the past decade, and the spectrum of exposures facing life sciences businesses continues to widen. Specialist knowledge gives brokers the tools to move well beyond standard insurance conversations.
Life sciences businesses face risks that rarely appear elsewhere. Kelly Ross-Howard, head of life science and allied health at Keystone Underwriting, describes an environment where growth and risk evolve in tandem. 'Life sciences businesses operate in a highly innovative environment where growth and risk often evolve together,' she says. 'As technologies advance and organisations expand, insurance needs to keep pace with the changing risk profile.' Expansion through global clinical trials, technology licensing and artificial intelligence to accelerate drug discovery creates new areas of exposure alongside commercial opportunity. Intellectual property disputes, cyber incidents, regulatory scrutiny and professional liability concerns are all increasing in frequency and complexity.
The average cost of cybercrime per report rose 50% from 2024 to 2025, according to the Australian Signals Directorate (ASD) Annual Cyber Threat Report 2024–25. The stakes are unusually high. A breach can expose clinical trial data, research findings, patient information and proprietary intellectual property. It can also compromise years of research investment. Insurers now treat multi-factor authentication, endpoint detection, employee training and incident response planning as standard underwriting requirements. 'As life sciences organisations become more dependent on connected technologies and digital platforms, cyber resilience is becoming a key differentiator from both risk management and insurance perspectives,' Ross-Howard says.
World Health Organization data records more than 2,500 clinical trials in Australia each year, an increase of around 60% over the last decade. Australia's reputation as a preferred destination is built on R&D incentives, academic partnerships and efficient regulatory pathways. Underwriting scrutiny is highest for novel therapies. Participant injury risks, regulatory obligations, data privacy requirements and cross-border exposures all contribute to a complex underwriting environment. Businesses involved in advanced therapies and gene-based treatments may face increased underwriting requirements and higher premiums. For brokers, early engagement with specialist underwriters can be critical in ensuring appropriate protection is in place before trial commencement.
For many life sciences organisations, intellectual property is the foundation of enterprise value. 'Many life sciences companies are built around a single technology platform or innovation,' Ross-Howard says. 'Protecting that intellectual property can be just as important as protecting physical assets or revenue streams.' Patent disputes, licensing disagreements, research collaboration conflicts and questions surrounding AI-generated intellectual property are all becoming more common. Investors and stakeholders are paying closer attention to how organisations protect and manage their IP assets. Interest in intellectual property insurance and specialist liability solutions is growing across the sector as a result.
Management liability and directors and officers (D&O) insurance are essential for both private and publicly listed life sciences businesses. The exposure is broad. Capital raising, shareholder expectations, regulatory investigations and employment-related disputes all generate significant exposure for directors and senior executives. Additional scrutiny is emerging around clinical trial disclosures, cyber incident management, AI governance and ESG reporting obligations. Employment practices claims rank among the most common management liability losses across the sector. 'Many businesses focus heavily on innovation and commercialisation, which is understandable,' Ross-Howard says. 'However, growth initiatives can also create new risks that require careful management and appropriate insurance protection.'
The broader market remains relatively competitive. Strong capacity is available across public and products liability, professional indemnity, clinical trials and cyber insurance. Underwriters exercise caution around advanced therapies, medical device manufacturers, AI-driven healthcare platforms and organisations with significant US exposure. Businesses that demonstrate strong governance, robust cyber controls, quality risk management and clear commercialisation strategies are generally achieving more favourable insurance outcomes. That distinction matters. Brokers who can help clients articulate their risk management frameworks are better placed to secure appropriate terms in a market where underwriter appetite varies sharply by therapy type and geography.
Keystone Underwriting is an Australian specialist underwriting agency that underwrites exclusively on behalf of certain underwriters at Lloyd's. Its product suite spans financial lines, liability, property, accident and sickness, medical malpractice, life sciences and specie. Direct access to experienced underwriters matters in a sector this specialised. 'The sector continues to present significant opportunities, but it also demands a deeper understanding of evolving risks,' Ross-Howard says. 'By working closely with brokers, we help clients navigate these challenges and build insurance programs that support innovation, growth and long-term resilience.' Brokers seeking specialist guidance can access exclusive insurance industry features covering life sciences and other complex risks.
Kelly Ross-Howard: head of life science and allied health, Keystone Underwriting; specialist in life sciences and allied health insurance; Keystone Underwriting underwrites exclusively on behalf of certain underwriters at Lloyd's and operates across financial lines, liability, property, accident and sickness, medical malpractice, life sciences and specie.